false
Hamburger Menu
Catalog
FDA Approval: Repotrectinib, a ROS1 and NTRK Inhib ...
FDA Approval: Repotrectinib, a ROS1 and NTRK Inhibitor
Podcast | English | 2023 | 37 Min
Create Account
Cost
$0.00
Credit
No Credit Offered
IASLC Lung Cancer Considered Podcast
Lung Cancer Considered host Dr. Stephen Liu moderates a discussion on the November 15, 2023, US FDA approval of repotrectinib for advanced NSCLC with a ROS1 gene fusion based on the single-arm, multi-cohort TRIDENT-1 trial.
Faculty
Podcast Hosts:
Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, USA
Podcast Guests:
Benjamin Besse, MD, PhD, Director of Clinical Research, Gustave Roussy, France
Jessica Lin, MD, Assistant Professor of Medicine, Harvard School of Medicine, Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital, USA
×
FDA Approval: Repotrectinib, a ROS1 and NTRK Inhibitor Course List
Login
User Login
Continue with Google
OR
Email
Required
Password
Required
Logging In…
Create Account
Forgot Password
×
Please select your language
1
English